Navigation Links
VIVUS to Present at Four Upcoming Investor Conferences in May
Date:4/29/2011

MOUNTAIN VIEW, Calif., April 28, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that VIVUS management will present an overview of the company at four investment conferences during the month of May.  The conference presentation schedule is as follows:Deutsche Bank Health Care ConferenceMay 4, 2011 at 11:20 a.m. ETPresented by: Timothy Morris, chief financial officerInterContinental Boston, Boston, MAJMP Securities 10th Annual Research ConferenceMay 9, 2011 at 9:00 a.m. PTPresented by: Dr. Barbara Troupin, senior director, medical affairsThe Ritz-Carlton, San Francisco, CABank of America Merrill Lynch 2011 Health Care ConferenceMay 11, 2011 at 4:20 p.m. PTPresented by: Peter Tam, presidentEncore Hotel, Las Vegas, NVUBS Global Specialty Pharmaceuticals ConferenceMay 25, 2011 at 2:00 p.m. BSTPresented by: Timothy Morris, chief financial officerUBS, One Finsbury Avenue, London, UKA live audio webcast and 30-day archive of the presentations will be available at http://ir.vivus.com.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development, QNEXA, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

CONTACT: VIVUS, Inc.Investor Relations:The Trout GroupTimothy E. MorrisBrian KorbChief Financial Officer

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Data on VIVUS Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
3. VIVUS to Present at the Needham and Company Life Sciences Conference
4. VIVUS to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. VIVUS to Present at Four Upcoming Healthcare Conferences
6. VIVUS Announces Positive Results From Two Phase 3 Studies; Obese Patients on Qnexa Achieve Average Weight Loss up to 14.7% and Significant Improvements in Co-Morbidities
7. VIVUS Reports Third Quarter 2009 Highlights and Financial Results
8. VIVUS to Present at Two Upcoming Investor Conferences
9. VIVUS to Present at Four Upcoming Investor Conferences
10. Data on VIVUS QNEXA to be Presented in Six Posters at The Obesity Societys Annual Meeting
11. VIVUS to Present at the 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... GEA Pharma Systems, G-CON Manufacturing ... of the INTERPHEX Exhibitor Awards for 2015 for ... Continuous, Miniature and Modular (PCMM) platform. PCMM comprises ... processing equipment, smart control systems and PODs (portable, ... inactive ingredients into bulk tablets. , PCMM ...
(Date:5/4/2015)... , May 4, 2015 Many ... granted. But for certain infants with rare, inherited ... are stark consequences of their impaired immune responses. ... Center have identified an important role for calcium ... from Mycobacterium tuberculosis, the bacterium causing tuberculosis (TB). ...
(Date:5/4/2015)... 2015 GliaCure, a privately-held biotechnology company ... neurological and neuropsychiatric disorders based on glial targets, ... patients in a Phase 1b clinical trial of ... as a potential disease-modifying treatment. GliaCure,s innovative approach ... it both promotes the clearance of amyloid and ...
(Date:5/4/2015)... May 4, 2015 /PRNewswire/ - The Fight Against ... pleased to announce the formation of Turnstone Biologics ... treatments for cancer that harness the patient,s own ... unique collaboration between the Children,s Hospital of ... McMaster University, the Ontario Institute for Cancer Research ...
Breaking Biology Technology:GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 2GEA Pharma Systems, G-CON Manufacturing and Pfizer Consortium Receives Best Technology Innovation Award at INTERPHEX 2015 3Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 2Researchers Discover A Novel And Unexpected Role For Calcium In Controlling Inflammation During Chronic Lung Infection 3GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 2Turnstone Biologics Inc. to accelerate clinical and commercial translation of cancer immunotherapies 3
... Feb. 12 AdvanDx announced it has named,Else ... Dako A/S, as Vice,President of Sales and Marketing. ... AdvanDx,s fast, accurate and easy-to-use in vitro,molecular diagnostic ... infectious pathogens. Ms. Trautner previously managed an,organization of ...
... /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: AEZS ; ... therapy and oncology, today reported that dosing of ... doxorubicin,has commenced in its Phase 2 trial in ... December 2007. This open-label,non-comparative multi-center Phase 2 trial ...
... Lasers to be Exclusively Featured in Leading Dental Education ... ... HOYA ConBio(TM), a global,leader in dental and aesthetic lasers, ... recognized dental education,company, in which VersaWave(TM) and DioDent(TM) Micro 980 ...
Cached Biology Technology:Molecular Diagnostics Leader AdvanDx Taps Former Dako Executive Vice President to Lead Global Sales and Marketing Expansion 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 4HOYA ConBio and The Hornbrook Group Announce Expanded Alliance 2HOYA ConBio and The Hornbrook Group Announce Expanded Alliance 3
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... Sweden , April 2, 2015 ... its touch fingerprint sensor FPC1025 from the distributor World ... will commence during Q2 2015 although the major part ... The sensors will be used by smartphone manufacturers in ... 110 MSEK is included in the communicated revenue guidance ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2
... Mayor Jerry Sanders today joined UC San Diego Chancellor ... announce their support for a regional partnership designed to ... Speaking at a news conference on the UC San ... Diego region, now home to more than 500 biotechnology ...
... in U.S. dollars have been awarded to Singapore ... related to asthma and other immune system disorders, ... grants were awarded by the Biomedical Research Council ... Research), the government agency driving Singapore,s transformation into ...
... Ohio Very few athletic trainers associated with National ... following best practice standards for managing asthma among their ... with asthma, the dangers of the condition can be ... to be incapacitating, or deadly. The lead report is ...
Cached Biology News:Regional partnership to develop algal biofuels gets backing of San Diego leaders 2Regional partnership to develop algal biofuels gets backing of San Diego leaders 3Regional partnership to develop algal biofuels gets backing of San Diego leaders 4Regional partnership to develop algal biofuels gets backing of San Diego leaders 5Regional partnership to develop algal biofuels gets backing of San Diego leaders 6Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 2Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 3Alzheimer's, asthma, cancer, malaria and TB focus of new Singapore grants 4Athletes with asthma need more help from their team trainers 2
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... The 2/3D Waver Shaker combines shaking and ... with a 330 x 330 mm stainless steel ... top incubator and cold room operation. The platform ... degree for a vigorous with action and rotation ...
...
Biology Products: